Medtronic 2015 Annual Report Download - page 27

Bryan C. Hanson, age 48, has been Executive Vice President and Group President, Minimally Invasive Therapies Group of the
Company since January 2015. Prior to that, he was Senior Vice President and Group President, Covidien since October 2014;
Senior Vice President and Group President, Medical Devices and United States of Covidien from October 2013 to September
2014; Senior Vice President and Group President of Covidien for the Surgical Solutions business from July 2011 to October
2013; and President of Covidien’s Energy-based Devices business from July 2006 to June 2011. Mr. Hanson held several other
positions of increasing responsibility in sales, marketing and general management with Covidien from October 1992 to July
2006.
Bradley E. Lerman, age 58, has been Senior Vice President, General Counsel and Corporate Secretary of the Company since
January 2015 and of Medtronic, Inc. since May 2014. Prior to that, he was Executive Vice President, General Counsel, and
Corporate Secretary at Federal National Mortgage Association (Fannie Mae) from October 2012 to May 2014; Senior Vice
President and Chief Litigation Counsel at Pfizer, Inc. from January 2009 to September 2012; Partner at Winston & Strawn from
August 1998 to January 2009; partner at Kirkland & Ellis from March 1996 to July 1998; Associate Independent Counsel from
October 1994 to March 1996; and Assistant U.S. Attorney in the Northern District of Illinois from February 1986 to September
1994.
Geoffrey S. Martha, age 45, has been Senior Vice President of Strategy and Business Development of the Company since
January 2015 and of Medtronic, Inc. since August 2011. Prior to that, he served as Managing Director of Business Development
at GE Healthcare from April 2007 to July 2011; General Manager for GE Capital Technology Finance Services from November
2003 to March 2007; Senior Vice President, Business Development for GE Capital Vendor Financial Services from February
2002 to October 2003; General Manager for GE Capital Colonial Pacific Leasing from February 2001 to January 2002; and
Vice President, Business Development for Potomac Federal, the GE Capital federal financing investment bank from May 1998
to January 2001.
Christopher J. O’Connell, age 48, has been Executive Vice President and Group President, Restorative Therapies Group of the
Company since January 2015 and of Medtronic, Inc. since August 2009. Prior to that, he was Senior Vice President and
President, Diabetes from October 2006 to August 2009; President of Medtronic’s Emergency Response Systems division from
May 2005 to October 2006; and Vice President of Sales and Marketing of Medtronic’s Cardiac Rhythm Disease Management
division from November 2001 to May 2005. Mr. O’Connell has served in various management positions since joining the
Company in 1994.
Carol A. Surface, age 49, has been Senior Vice President and Chief Human Resources Officer of the Company since January
2015 and of Medtronic, Inc. since September 2013. Prior to that, she was the Executive Vice President and Chief Human
Resources Officer at Best Buy Co., Inc. from March 2010 to September 2013, and held a series of HR leadership roles at
PepsiCo Inc., from May 2000 to March 2010.
Robert ten Hoedt, age 54, has been Executive Vice President and President, EMEAC of the Company since January 2015 and
of Medtronic, Inc. since May 2014. Prior to that, he was Senior Vice President and President, EMEA and Canada from 2009 to
2014; Vice President CardioVascular Europe and Central Asia from 2006 to 2009; Vice President and General Manager,
Vitatron from 1999 to 2006; Gastro-Uro leader from 1994 to 1999; and Marketing Manager, Neurological from 1991 to 1994.
Item 1A. Risk Factors
Investing in us involves a variety of risks and uncertainties, known and unknown, including, among others, those discussed
below. Each of the following risks should be carefully considered. Based on the information currently known to us, we believe
the following information identifies the most significant risk factors affecting our Company. However, the risks and
uncertainties described below are not the only ones related to our businesses and are not necessarily listed in the order of their
importance. Additional risks and uncertainty not presently known to us or that we currently believe to be immaterial may also
adversely affect our business.
Risks Relating to the Company
We operate in a highly competitive industry and we may be unable to compete effectively.
We compete in both the therapeutic and diagnostic medical markets in approximately 160 countries throughout the world. These
markets are characterized by rapid change resulting from technological advances and scientific discoveries. In the product lines
in which we compete, we face a mixture of competitors ranging from large manufacturers with multiple business lines to small
17